Insilico Medicine Raises $60M in Series D Financing
Summary
The company intends to use the funds to further bolster its financial position and accelerate the growth of its advancing pipeline, including its lead program which is currently in a Phase I study, and continued development of its Pharma.AI platform. The proceeds will also fund ongoing global expansion and planned strategic initiatives, including a fully automated, AI-driven robotic drug discovery laboratory, and fully robotic biological data factory to complement Insilico’s vast curated data assets. Led by Alex Zhavoronkov, PhD, Founder and CEO, Insilico Medicine is a clinical stage end-to-end artificial intelligence (AI)-driven drug discovery company connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. Since the previous round of financing, Insilico has developed a growing portfolio in frontier areas empowered by its proprietary AI platform. Notably, Insilico achieved its first major milestone and nominated a preclinical candidate for the QPCTL program for cancer immunotherapy in less than 40 days into the strategic collaboration with Fosun Pharma.
Funding
Review available funding amount, funding date, investors, and linked company information related to Insilico Medicine Raises $60M in Series D Financing in the interactive ISVWorld profile.